- Home
- NMRK vs TVTX Comparison
NMRK vs TVTX Comparison
Compare NMRK & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRK | TVTX |
|---|---|---|
| Founded | 1929 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMRK | TVTX |
|---|---|---|
| Price | $17.31 | $29.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $19.60 | ★ $37.21 |
| AVG Volume (30 Days) | 776.2K | ★ 3.2M |
| Earning Date | 02-25-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 94.50 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $3,160,782,000.00 | $435,826,000.00 |
| Revenue This Year | $21.82 | $120.02 |
| Revenue Next Year | $9.86 | $37.00 |
| P/E Ratio | $29.01 | ★ N/A |
| Revenue Growth | 20.95 | ★ 114.22 |
| 52 Week Low | $9.65 | $12.91 |
| 52 Week High | $19.84 | $42.13 |
Technical Indicators
Market Signals| Indicator | NMRK | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 38.91 |
| Support Level | $16.86 | $26.78 |
| Resistance Level | $18.25 | $30.16 |
| Average True Range (ATR) | 0.63 | 2.13 |
| MACD | -0.01 | -0.46 |
| Stochastic Oscillator | 48.65 | 46.47 |
Price Performance
Historical ComparisonAbout NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.